NUVB - Latest News
Nuvation Bio Inc. (NUVB), operates in Healthcare / Biotechnology, trades on NYSE.
Market capitalization stands near $2.16B. Beta to the broader market is 1.52.
The article list below shows the most recent NUVB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent NUVB Headlines
Nuvation Bio Q2 Earnings Call Highlights
marketbeat.com - Aug 8, 2026
Nuvation Bio NYSE: NUVB reported second-quarter total revenue of $31. 7 million, including $23.
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
seekingalpha.com - Aug 6, 2026
Nuvation Bio Inc.
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
zacks.com - Aug 6, 2026
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
prnewswire.com - Aug 6, 2026
Achieved $31. 7 million in second quarter 2026 total revenue, including $23.
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
prnewswire.com - Aug 4, 2026
Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key patient subgroups NEW YORK, Aug. 4, 2026 /PRNewswire/
How News Affects NUVB Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track NUVB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked NUVB news questions
- What is the latest NUVB news headline?
- The most recent NUVB headline (Aug 8, 2026) is "Nuvation Bio Q2 Earnings Call Highlights". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the NUVB news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What NUVB news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual NUVB options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.